Skip to main content
SpringerLink
Log in

Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response

  • Book
  • © 2009

Overview

Editors:
  1. Federico Innocenti

    1. Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Comprehensive reference for researchers in the field of cancer pharmacogenomics and clinicians, from both academia and industry
  • Provides a collection of multi-disciplinary topics
  • Covers the most important aspects of pharmacogenomics applied to cancer patients

Part of the book series: Cancer Drug Discovery and Development (CDD&D)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (21 chapters)

  1. Front Matter

    Pages i-xiv
    Download chapter PDF

  2. Genomic Experimental Approaches in Oncology

    1. Front Matter

      Pages 1-1
      Download chapter PDF

    2. Toward the Realization of the Promise of Microarrays in Oncology

      • Natalie Stickle, Neil Winegarden
      Pages 3-18

    3. Cell-Based Models to Identify Genetic Variants Contributing to Anticancer Drug Response

      • M. Eileen Dolan, Howard McLeod
      Pages 19-31

    4. Proteomic Analysis in Cancer Patients

      • Yasuhiro Kuramitsu, Kazuyuki Nakamura
      Pages 33-45

    5. MicroRNAs and Discovery of New Targets

      • Soken Tsuchiya, Yasushi Okuno, Gozoh Tsujimoto
      Pages 47-56

    6. Pharmacogenomics of the National Cancer Institute’s 60-Tumor Cell Panel

      • Anders Wallqvist, Ruili Huang, David G. Covell
      Pages 57-74

    7. Use of Single-Nucleotide Polymorphism Array for Tumor Aberrations in Gene Copy Numbers

      • Kwong-Kwok Wong
      Pages 75-88

  3. Pharmacogenomics of Toxicity and Response of Chemotherapy

    1. Front Matter

      Pages 90-90
      Download chapter PDF

    2. Concordance Between Tumor and Germline DNA

      • Sharon Marsh
      Pages 91-101

    3. Epidermal Growth Factor Receptor Mutations and Sensitivity to Selective Kinase Inhibitors in Human Lung Cancer

      • Anurag Singh, Sreenath V. Sharma, Jeffrey Settleman
      Pages 103-126

    4. BCR-ABL Mutations and Imatinib Resistance in Chronic Myeloid Leukemia Patients

      • Mark R. Litzow
      Pages 127-150

    5. Role of Thymidylate Synthase Gene Variations in Colorectal Cancer Patients

      • Georg Lurje, Heinz-Josef Lenz
      Pages 151-172

    6. Thiopurines in the Treatment of Childhood Acute Lymphoblastic Leukemia and Genetic Variants of the Thiopurine S-Methyltransferase Gene

      • Martin Stanulla, Elke Schaeffeler, Matthias Schwab
      Pages 173-201

    7. Impact of Polymorphisms on the Clinical Outcomes of Monoclonal Antibody Therapy Against Hematologic Malignancies

      • Dong Hwan Kim
      Pages 203-229

    8. DNA Repair and Mitotic Checkpoint Genes as Potential Predictors of Chemotherapy Response in Non-Small-Cell Lung Cancer

      • Rafael Rosell, Miquel Taron, Mariacarmela Santarpia, Fernanda Salazar, Jose Luis Ramirez, Miguel Angel Molina
      Pages 231-247

    9. Dihydropyrimidine Dehydrogenase (Dpyd) Gene Polymorphism: Portrait of a Serial Killer

      • Joseph Ciccolini, Cédric Mercier, Gérard Milano
      Pages 249-265

    10. Impact of UDP-Glucuronosyltransferase 1A Haplotypes on Irinotecan Treatment

      • Kimie Sai, Hironobu Minami, Yoshiro Saito, Jun-ichi Sawada
      Pages 267-286

    11. Microarray Profiling in Breast Cancer Patients

      • Yong Qian, Xianglin Shi, Vincent Castranova, Nancy L. Guo
      Pages 287-298

    12. Role of the Folate-Pathway and the Thymidylate Synthase Genes in Pediatric Acute Lymphoblastic Leukemia Treatment Response

      • Lea Cunningham, Richard Aplenc
      Pages 299-310
Back to top

Keywords

About this book

Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response provides the most comprehensive body of knowledge available on the role of genetic and genomic variation in the individualization of drug therapies in cancer patients. As a consequence of the intrinsic chromosomal and genetic instability of the tumor genome, it is generally believed that tailoring of chemotherapy in cancer - tients might be achieved by molecular analysis of patient tumor DNA. In addition, to reduce the toxicity risk of patients, the tumor DNA information should be in- grated with the available data on polymorphic drug-metabolizing enzyme and tra- porter genes mediating the exposure of patients to active drugs and/or their active metabolites. The chapters of this book clearly show how DNA information from both the host (germline) and the tumor should be taken into account for rational selection of drug therapies in cancer patients, an aspect that received little attention, despite its importance. The availability of new molecular approaches to the selection of drug therapy is an emerging need, because the traditional approach based on the evaluation of patient and tumor characteristics is clearly far from optimal. Many treated patients do not experience signi?cant bene?ts from the treatment, while they often experience moderate to severe toxicities. In addition, the development and clinical use of novel molecularly targeted agents (alone or in combination with classical cytotoxic therapy) requires the und- standing of the molecular features of the tumors and the identi?cation of tumor markers of response.

Reviews

From the reviews:

"The chapters of this book, written by outstanding scientists in the field of cancer pharmacogenomics, clearly show how DNA information from both the host and the tumor should be taken into account for rational selection of drug therapies in cancer patients. … the book provides a comprehensive and in-depth view of the field of cancer pharmacogenomics. The book is informative for clinicians, for people involved in development of cancer therapeutics on industrial level, and any scientists who are interested in cancer biology." (C. Altaner, Neoplasma, June, 2009)

"The chapters of this book, written by outstanding scientists in the field of cancer pharmacogenomics … . the book provides a comprehensive and in-depth view of the field of cancer pharmacogenomics. The book is informative for clinicians, for people involved in development of cancer therapeutics on industrial level, and any scientists who are interested in cancer biology." (C. Altaner, Neoplasma, April, 2009)

Editors and Affiliations

  • Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, USA

    Federico Innocenti

Bibliographic Information

  • Book Title: Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response

  • Editors: Federico Innocenti

  • Series Title: Cancer Drug Discovery and Development

  • DOI: https://doi.org/10.1007/978-1-60327-088-5

  • Publisher: Humana Totowa, NJ

  • eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)

  • Copyright Information: Humana Press 2009

  • Hardcover ISBN: 978-1-58829-646-7Published: 23 October 2008

  • Softcover ISBN: 978-1-61737-694-8Published: 19 November 2010

  • eBook ISBN: 978-1-60327-088-5Published: 30 October 2008

  • Series ISSN: 2196-9906

  • Series E-ISSN: 2196-9914

  • Edition Number: 1

  • Number of Pages: XIV, 378

  • Number of Illustrations: 50 b/w illustrations, 3 illustrations in colour

  • Topics: Cancer Research, Pharmacology/Toxicology, Human Genetics

Publish with us

Policies and ethics

Back to top

Search

Navigation